<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005898</url>
  </required_header>
  <id_info>
    <org_study_id>199/15109</org_study_id>
    <secondary_id>UMN-MT-1999-05</secondary_id>
    <secondary_id>UMN-MT9905</secondary_id>
    <nct_id>NCT00005898</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the probability of engraftment with total body irradiation,&#xD;
      cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically&#xD;
      identical donor, T-cell depleted hematopoietic cell transplantation in patients with&#xD;
      Fanconi's anemia.&#xD;
&#xD;
      II. Determine the incidence of acute and chronic graft-versus-host disease in these patients&#xD;
      after undergoing this treatment regimen.&#xD;
&#xD;
      III. Determine the one-year survival rate in these patients after undergoing this treatment&#xD;
      regimen.&#xD;
&#xD;
      IV. Determine the toxicity of this treatment regimen in these patients. V. Determine the&#xD;
      incidence of relapse in patients with myelodysplastic syndrome or acute myeloid leukemia&#xD;
      after undergoing this treatment regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Donor bone marrow, peripheral blood, or umbilical cord blood is processed&#xD;
      to harvest CD34+ cells.&#xD;
&#xD;
      Patients receive preparative cytoreductive therapy comprising total body irradiation on day&#xD;
      -6; cyclophosphamide IV over 2 hours on days -5 to -2; fludarabine IV over 30 minutes on days&#xD;
      -5 to -2; methylprednisone IV on days -5 to 24; anti-thymocyte globulin IV over 4-6 hours on&#xD;
      days -5 to -1; cyclosporine IV over 2 hours every 12 hours (every 8 hours for patients less&#xD;
      than 40 kg in weight) on days -3 to 180, and then tapering in the absence of&#xD;
      graft-versus-host disease; hematopoietic cell transplantation on day 0; and filgrastim&#xD;
      (G-CSF) IV starting on day 1 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed at days 60, 90, and 180, and then annually for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Fanconi's Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Patients with a diagnosis of Fanconi's anemia AND Aplastic anemia OR Myelodysplastic&#xD;
             syndrome OR Acute leukemia with or without chromosomal anomalies Aplastic anemia as&#xD;
             defined by having at least one of the following: Platelet count less than 20,000/mm3&#xD;
             Absolute neutrophil count less than 500/mm3 Hemoglobin less than 8 g/dL&#xD;
&#xD;
          -  Myelodysplastic syndrome with multilineage dysplasia With or without chromosomal&#xD;
             anomalies&#xD;
&#xD;
          -  Hematologic malignancy (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, or&#xD;
             B-cell non-Hodgkin's lymphoma)&#xD;
&#xD;
          -  No greater than 30% blasts in bone marrow or greater than 5% blasts in peripheral&#xD;
             blood&#xD;
&#xD;
          -  No active CNS leukemia at time of transplantation&#xD;
&#xD;
          -  Must have an HLA A, B, DRB1 identical or 1 antigen mismatched related (nonsibling) or&#xD;
             unrelated bone marrow, peripheral blood, or umbilical cord blood donor&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Radiotherapy: No prior radiotherapy that would preclude total body irradiation&#xD;
&#xD;
          -  Surgery: Not specified&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Performance status: Karnofsky 70-100% OR Lansky 50-100%&#xD;
&#xD;
          -  Hematopoietic: See Disease Characteristics&#xD;
&#xD;
          -  Hepatic: No hepatic failure (e.g., coagulopathy or ascites)&#xD;
&#xD;
          -  Renal: Creatinine clearance at least 40 mL/min&#xD;
&#xD;
          -  Cardiovascular: Ejection fraction at least 45%&#xD;
&#xD;
          -  Other: No active uncontrolled infection within one week of transplantation No&#xD;
             malignant solid tumor (e.g., squamous cell carcinoma of the head, neck, or cervix)&#xD;
             within 2 years of transplantation Not pregnant or nursing Negative pregnancy test&#xD;
             Fertile patients must use effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Wagner, Jr.</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 2, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

